Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Competition Archive
The review found no meaningful increase in serious safety risks compared with placebo, including severe hypoglycemia or acute pancreatitis
State-of-the-Art Facility : Our medspa is equipped with the latest technology and adheres to the highest standards of cleanliness and safety
BPC-157: The Gut & Tissue Repair Specialist Body Protection Compound-157, or BPC-157 , is renowned for its potent healing properties, especially for the gastrointestinal tract
US$ 29.00
US$ 22.25
US$ 21.69
US$ 20.20
US$ 25.11
US$ 23.02
US$ 27.81
US$ 22.58
